Delivery of interferons and siRNA targeting STAT3 using lentiviral vectors suppresses the growth of murine melanoma

Cancer Gene Therapy

Volumn 19, Issue 12, 2012, Pages 822-827

  Wang, X ^a   Liu, P ^a   Liu, H ^a   Yang, W ^a   Liu, Z ^a   Zhuo, Z ^a   Gao, Y ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

cancer immunotherapy; interferon; lentiviral vectors; signal transducer and activator of transcription 3

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; GAMMA INTERFERON; INTERFERON; LENTIVIRUS VECTOR; SMALL INTERFERING RNA; STAT3 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL VIABILITY; CONTROLLED STUDY; IN VITRO STUDY; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; RNA INTERFERENCE; TREATMENT RESPONSE;

ANIMALS; CELL LINE, TUMOR; DOWN-REGULATION; GENETIC THERAPY; GENETIC VECTORS; HUMANS; IMMUNOTHERAPY; INTERFERONS; LENTIVIRUS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; RNA, SMALL INTERFERING; STAT3 TRANSCRIPTION FACTOR;

MURINAE;

EID: 84869215257     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2012.65     Document Type: Article

References (39)

1. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011; 331: 1565-1570.
2. Rosenberg SA. Raising the bar: the curative potential of human cancer immunotherapy. Sci Transl Med 2012; 4: 127ps8.
3. Dunn GP, Bruce AT, Sheehan KC, Shankaran V, Uppaluri R, Bui JD et al. A critical function for type I interferons in cancer immunoediting. Nat Immunol 2005; 6: 722-729. (Pubitemid 41716746)
4. Gao Y, Yang W, Pan M, Scully E, Girardi M, Augenlicht LH et al. beta delta T cells provide an early source of interferon gamma in tumor immunity. J Exp Med 2003; 198: 433-442. (Pubitemid 36976054)
5. Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 1998; 95: 7556-7561. (Pubitemid 28293291)
6. Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat Rev Immunol 2006; 6: 836-848. (Pubitemid 44631652)
7. Wang BX, Rahbar R, Fish EN. Interferon: current status and future prospects in cancer therapy. J Interferon Cytokine Res 2011; 31: 545-552.
8. Bowman T, Broome MA, Sinibaldi D, Wharton W, Pledger WJ, Sedivy JM et al. Stat3-mediated Myc expression is required for Src transformation and PDGFinduced mitogenesis. Proc Natl Acad Sci USA 2001; 98: 7319-7324. (Pubitemid 32567946)
9. Gritsko T, Williams A, Turkson J, Kaneko S, Bowman T, Huang M et al. Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res 2006; 12: 11-19. (Pubitemid 43166170)
10. Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 2002; 21: 2000-2008. (Pubitemid 34270888)
11. Wang T, Niu G, Kortylewski M, Burdelya L, Shain K, Zhang S et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 2004; 10: 48-54. (Pubitemid 38524698)
12. Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 2007; 7: 41-51. (Pubitemid 46020826)
13. Kortylewski M, Kujawski M, Wang T, Wei S, Zhang S, Pilon-Thomas S et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 2005; 11: 1314-1321. (Pubitemid 41752912)
14. Kasprzycka M, Marzec M, Liu X, Zhang Q, Wasik MA. Nucleophosmin/ anaplastic lymphoma kinase (NPM/ALK) oncoprotein induces the T regulatory cell phenotype by activating STAT3. Proc Natl Acad Sci USA 2006; 103: 9964-9969. (Pubitemid 43993606)
15. Kong LY, Gelbard A, Wei J, Reina-Ortiz C, Wang Y, Yang EC et al. Inhibition of p-STAT3 enhances IFN-alpha efficacy against metastatic melanoma in a murine model. Clin Cancer Res 2010; 16: 2550-2561.
16. Escors D, Breckpot K. Lentiviral vectors in gene therapy: their current status and future potential. Arch Immunol Ther Exp (Warsz) 2010; 58: 107-119.
17. Cartier N, Hacein-Bey-Abina S, Bartholomae CC, Veres G, Schmidt M, Kutschera I et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 2009; 326: 818-823.
18. Esslinger C, Chapatte L, Finke D, Miconnet I, Guillaume P, Levy F et al. In vivo administration of a lentiviral vaccine targets DCs and induces efficient CD8(\+) T cell responses. J Clin Invest 2003; 111: 1673-1681. (Pubitemid 38057749)
19. Rowe HM, Lopes L, Ikeda Y, Bailey R, Barde I, Zenke M et al. Immunization with a lentiviral vector stimulates both CD4 and CD8 T cell responses to an ovalbumin transgene. Mol Ther 2006; 13: 310-319. (Pubitemid 43056896)
20. Kutner RH, Zhang XY, Reiser J. Production, concentration and titration of pseudotyped HIV-1-based lentiviral vectors. Nat Protoc 2009; 4: 495-505.
21. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
22. Street SE, Cretney E, Smyth MJ. Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. Blood 2001; 97: 192-197. (Pubitemid 32061260)
23. Mitra-Kaushik S, Harding J, Hess J, Schreiber R, Ratner L. Enhanced tumorigenesis in HTLV-1 tax-transgenic mice deficient in interferon-gamma. Blood 2004; 104: 3305-3311. (Pubitemid 39507150)
24. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001; 410: 1107-1111. (Pubitemid 32391043)
25. Passalacqua R, Buzio C, Buti S, Porta C, Labianca R, Pezzuolo D et al. Phase III, randomised, multicentre trial of maintenance immunotherapy with low-dose interleukin-2 and interferon-alpha for metastatic renal cell cancer. Cancer Immunol Immunother 2010; 59: 553-561.
26. Kirkwood J. Cancer immunotherapy: the interferon-alpha experience. Semin Oncol 2002; 29(3 Suppl 7): 18-26.
27. Gleave ME, Elhilali M, Fradet Y, Davis I, Venner P, Saad F et al. Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group. N Engl J Med 1998; 338: 1265-1271. (Pubitemid 28216580)
28. Wiesenfeld M, O'Connell MJ, Wieand HS, Gonchoroff NJ, Donohue JH, Fitzgibbons Jr RJ et al. Controlled clinical trial of interferon-gamma as postoperative surgical adjuvant therapy for colon cancer. J Clin Oncol 1995; 13: 2324-2329.
29. Lu W, Fidler IJ, Dong Z. Eradication of primary murine fibrosarcomas and induction of systemic immunity by adenovirus-mediated interferon beta gene therapy. Cancer Res 1999; 59: 5202-5208. (Pubitemid 29503983)
30. Jonasch E, Haluska FG. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist 2001; 6: 34-55. (Pubitemid 32155814)
31. He Y, Zhang J, Donahue C, Falo Jr LD. Skin-derived dendritic cells induce potent CD8(\+) T cell immunity in recombinant lentivector-mediated genetic immunization. Immunity 2006; 24: 643-656.
32. Stegmeier F, Hu G, Rickles RJ, Hannon GJ, Elledge SJ. A lentiviral microRNA-based system for single-copy polymerase II-regulated RNA interference in mammalian cells. Proc Natl Acad Sci USA 2005; 102: 13212-13217. (Pubitemid 41325003)
33. Shin KJ, Wall EA, Zavzavadjian JR, Santat LA, Liu J, Hwang JI et al. A single lentiviral vector platform for microRNA-based conditional RNA interference and coordinated transgene expression. Proc Natl Acad Sci USA 2006; 103: 13759-13764. (Pubitemid 44413981)
34. De Palma M, Mazzieri R, Politi LS, Pucci F, Zonari E, Sitia G et al. Tumor-targeted interferon-alpha delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis. Cancer Cell 2008; 14: 299-311.
35. Liu P, Zhang C, Chen J, Zhang R, Ren J, Huang Y et al. Combinational therapy of interferon-alpha and chemotherapy normalizes tumor vasculature by regulating pericytes including the novel marker RGS5 in melanoma. J Immunother 2011; 34: 320-326.
36. Sundstedt A, Celander M, Hedlund G. Combining tumor-targeted superantigens with interferon-alpha results in synergistic anti-tumor effects. Int Immunopharmacol 2008; 8: 442-452. (Pubitemid 351221434)
37. Brown L, Roda J, Terrell C, Chaudhury AR, Crespin T, Carson WE et al. Interferon alpha and CPG oligodeoxynucleotides elicit additive immunostimulatory and antitumor effects. Surgery 2006; 140: 297-306. (Pubitemid 44176072)
38. Zaidi MR, Davis S, Noonan FP, Graff-Cherry C, Hawley TS, Walker RL et al. Interferon-gamma links ultraviolet radiation to melanomagenesis in mice. Nature 2011; 469: 548-553.
39. He YF, Wang XH, Zhang GM, Chen HT, Zhang H, Feng ZH. Sustained low-level expression of interferon-gamma promotes tumor development: potential insights in tumor prevention and tumor immunotherapy. Cancer Immunol Immunother 2005; 54: 891-897. (Pubitemid 40991331)